| review article | Q7318358 |
| scholarly article | Q13442814 |
| P2093 | author name string | Hiroaki Kataoka | |
| Makiko Kawaguchi | |||
| P2860 | cites work | Induction of hepatocyte growth factor in fibroblasts by tumor-derived factors affects invasive growth of tumor cells: in vitro analysis of tumor-stromal interactions | Q73555198 |
| Inhibition of growth, invasion, and metastasis of human pancreatic carcinoma cells by NK4 in an orthotopic mouse model | Q74631050 | ||
| Functional characterization of Kunitz domains in hepatocyte growth factor activator inhibitor type 2 | Q77408476 | ||
| Paradoxically enhanced immunoreactivity of hepatocyte growth factor activator inhibitor type 1 (HAI-1) in cancer cells at the invasion front | Q80836348 | ||
| Gene expression profile of papillary thyroid cancer: sources of variability and diagnostic implications | Q81448413 | ||
| Characterization of a novel, membrane-bound, 80-kDa matrix-degrading protease from human breast cancer cells. Monoclonal antibody production, isolation, and localization | Q95823944 | ||
| Pegylated kunitz domain inhibitor suppresses hepsin-mediated invasive tumor growth and metastasis | Q24309317 | ||
| Identification and cloning of human placental bikunin, a novel serine protease inhibitor containing two Kunitz domains | Q24315141 | ||
| Purification and cloning of hepatocyte growth factor activator inhibitor type 2, a Kunitz-type serine protease inhibitor | Q24321843 | ||
| Hepatocyte growth factor activator inhibitor, a novel Kunitz-type serine protease inhibitor | Q24322087 | ||
| Biological Activation of pro-HGF (Hepatocyte Growth Factor) by Urokinase Is Controlled by a Stoichiometric Reaction | Q57281116 | ||
| Processing of hepatocyte growth factor to the heterodimeric form is required for biological activity | Q67543328 | ||
| Proteolytic activation of hepatocyte growth factor in response to tissue injury | Q72303094 | ||
| Extracellular proteolytic cleavage by urokinase is required for activation of hepatocyte growth factor/scatter factor | Q24555664 | ||
| Reverse biochemistry: use of macromolecular protease inhibitors to dissect complex biological processes and identify a membrane-type serine protease in epithelial cancer and normal tissue | Q24614528 | ||
| Hepsin activates pro-hepatocyte growth factor and is inhibited by hepatocyte growth factor activator inhibitor-1B (HAI-1B) and HAI-2. | Q27863809 | ||
| Tumors: wounds that do not heal. Similarities between tumor stroma generation and wound healing | Q28131793 | ||
| Distribution of hepatocyte growth factor activator inhibitor type 1 (HAI-1) in human tissues. Cellular surface localization of HAI-1 in simple columnar epithelium and its modulated expression in injured and regenerative tissues | Q28142489 | ||
| Unusual proteolytic activation of pro-hepatocyte growth factor by plasma kallikrein and coagulation factor XIa | Q28206392 | ||
| Hepatocyte growth factor activator inhibitor 2/placental bikunin (HAI-2/PB) gene is frequently hypermethylated in human hepatocellular carcinoma | Q28236057 | ||
| Tumor suppressor activity and epigenetic inactivation of hepatocyte growth factor activator inhibitor type 2/SPINT2 in papillary and clear cell renal cell carcinoma | Q28254125 | ||
| Assignment1 of human putative tumor suppressor genes ST13 (alias SNC6) and ST14 (alias SNC19) to human chromosome bands 22q13 and 11q24-->q25 by in situ hybridization | Q28295812 | ||
| Matriptase autoactivation is tightly regulated by the cellular chemical environments | Q28541983 | ||
| Accessories to the crime: functions of cells recruited to the tumor microenvironment | Q29620161 | ||
| Hepatocyte growth factor activator inhibitor types 1 and 2 are expressed by tubular epithelium in kidney and down-regulated in renal cell carcinoma | Q31034992 | ||
| Increased expression of matriptase is associated with histopathologic grades of cervical neoplasia | Q33219603 | ||
| The ratio of Matriptase/HAI-1 mRNA is higher in colorectal cancer adenomas and carcinomas than corresponding tissue from control individuals | Q33248805 | ||
| Pericellular activation of hepatocyte growth factor by the transmembrane serine proteases matriptase and hepsin, but not by the membrane-associated protease uPA. | Q33518855 | ||
| Deregulated matriptase causes ras-independent multistage carcinogenesis and promotes ras-mediated malignant transformation | Q33917709 | ||
| Structure-function analysis of hepatocyte growth factor: identification of variants that lack mitogenic activity yet retain high affinity receptor binding | Q33938013 | ||
| Multiple myeloma cells catalyze hepatocyte growth factor (HGF) activation by secreting the serine protease HGF-activator | Q34323936 | ||
| Functional analysis of HGF/MET signaling and aberrant HGF-activator expression in diffuse large B-cell lymphoma. | Q34454578 | ||
| A novel signaling axis of matriptase/PDGF-D/ß-PDGFR in human prostate cancer | Q34683885 | ||
| Matriptase: potent proteolysis on the cell surface | Q34809525 | ||
| c-Met-induced epithelial carcinogenesis is initiated by the serine protease matriptase | Q34883707 | ||
| Delineation of matriptase protein expression by enzymatic gene trapping suggests diverging roles in barrier function, hair formation, and squamous cell carcinogenesis | Q35088270 | ||
| Roles of hepatocyte growth factor (HGF) activator and HGF activator inhibitor in the pericellular activation of HGF/scatter factor | Q35144580 | ||
| Expression of serine protease SNC19/matriptase and its inhibitor hepatocyte growth factor activator inhibitor type 1 in normal and malignant tissues of gastrointestinal tract | Q35621356 | ||
| Hepatocyte growth factor (HGF) autocrine activation predicts sensitivity to MET inhibition in glioblastoma | Q35673676 | ||
| Suppression of Tumorigenicity-14, encoding matriptase, is a critical suppressor of colitis and colitis-associated colon carcinogenesis | Q35823094 | ||
| Platelet-derived growth factor-C (PDGF-C) activation by serine proteases: implications for breast cancer progression | Q35929823 | ||
| Overexpression and activation of hepatocyte growth factor/scatter factor in human non-small-cell lung carcinomas. | Q36136355 | ||
| Hepatocyte growth factor and the Met system as a mediator of tumor-stromal interactions. | Q36384594 | ||
| Thrombin induces tumor growth, metastasis, and angiogenesis: Evidence for a thrombin-regulated dormant tumor phenotype | Q36650343 | ||
| The hepatocyte growth factor regulatory factors in human breast cancer | Q44735694 | ||
| Down-regulation of HAI-1 is associated with poor-differentiation status of colorectal cancer | Q44806334 | ||
| CVS-3983, a selective matriptase inhibitor, suppresses the growth of androgen independent prostate tumor xenografts | Q45059676 | ||
| Hepatocyte growth factor activator is a serum activator of single-chain precursor macrophage-stimulating protein. | Q46003940 | ||
| Expression of matriptase and clinical outcome of human endometrial cancer. | Q46011519 | ||
| Serum hepatocyte growth factor activator (HGFA) in benign prostatic hyperplasia and prostate cancer | Q46590851 | ||
| Induction of hepatocyte growth factor activator gene expression under hypoxia activates the hepatocyte growth factor/c-Met system via hypoxia inducible factor-1 in pancreatic cancer | Q46636420 | ||
| A novel biomarker for staging human prostate adenocarcinoma: overexpression of matriptase with concomitant loss of its inhibitor, hepatocyte growth factor activator inhibitor-1. | Q46956111 | ||
| Hepatocyte growth factor activator inhibitor type 1 inhibits protease activity and proteolytic activation of human airway trypsin-like protease. | Q51764334 | ||
| Potent and specific inhibition of the biological activity of the type-II transmembrane serine protease matriptase by the cyclic microprotein MCoTI-II. | Q52649083 | ||
| Expression of matriptase correlates with tumour progression and clinical prognosis in oral squamous cell carcinoma. | Q53075335 | ||
| Activation of hepatocyte growth factor by proteolytic conversion of a single chain form to a heterodimer | Q54260129 | ||
| The role of hepatocyte growth factor activator inhibitor (HAI)-1 and HAI-2 in endometrial cancer. | Q54415251 | ||
| Epigenetic inactivation of SPINT2 is associated with tumor suppressive function in esophageal squamous cell carcinoma. | Q54544469 | ||
| Clinical relevance of hepsin and hepatocyte growth factor activator inhibitor type 2 expression in renal cell carcinoma. | Q55043279 | ||
| The cutting edge: membrane-anchored serine protease activities in the pericellular microenvironment | Q36923138 | ||
| Potent inhibition and global co-localization implicate the transmembrane Kunitz-type serine protease inhibitor hepatocyte growth factor activator inhibitor-2 in the regulation of epithelial matriptase activity | Q36944800 | ||
| Elevated serum concentrations of activated hepatocyte growth factor activator in patients with multiple myeloma | Q37137157 | ||
| Imbalanced matriptase pericellular proteolysis contributes to the pathogenesis of malignant B-cell lymphomas | Q37218234 | ||
| A functional domain in the heavy chain of scatter factor/hepatocyte growth factor binds the c-Met receptor and induces cell dissociation but not mitogenesis | Q37329953 | ||
| Coordinate action of membrane-type matrix metalloproteinase-1 (MT1-MMP) and MMP-2 enhances pericellular proteolysis and invasion | Q37690802 | ||
| Hepatocyte growth factor activator (HGFA): pathophysiological functions in vivo | Q37733681 | ||
| MET signalling: principles and functions in development, organ regeneration and cancer | Q37811895 | ||
| Hepatocyte growth factor twenty years on: Much more than a growth factor | Q37825664 | ||
| Developing biomarkers to predict benefit from HGF/MET pathway inhibitors | Q38150768 | ||
| TMPRSS13, a type II transmembrane serine protease, is inhibited by hepatocyte growth factor activator inhibitor type 1 and activates pro‐hepatocyte growth factor | Q38339809 | ||
| Activation of hepatocyte growth factor by the plasminogen activators uPA and tPA. | Q38507554 | ||
| Overexpression of matriptase correlates with poor prognosis in esophageal squamous cell carcinoma | Q39061621 | ||
| Loss of hepatocyte growth factor activator inhibitor type 1 participates in metastatic spreading of human pancreatic cancer cells in a mouse orthotopic transplantation model | Q39074016 | ||
| Hepatocyte growth factor activator inhibitor type 1 is a suppressor of intestinal tumorigenesis. | Q39187421 | ||
| Regulation of pericellular proteolysis by hepatocyte growth factor activator inhibitor type 1 (HAI-1) in trophoblast cells | Q39224627 | ||
| Loss of membrane-bound serine protease inhibitor HAI-1 induces oral squamous cell carcinoma cells' invasiveness. | Q39409341 | ||
| Cleavage of hepatocyte growth factor activator inhibitor-1 by membrane-type MMP-1 activates matriptase | Q39437208 | ||
| Hepatocyte growth factor activator inhibitor type 1 suppresses metastatic pulmonary colonization of pancreatic carcinoma cells. | Q39618840 | ||
| Epigenetic inactivation and tumor suppressor activity of HAI-2/SPINT2 in gastric cancer | Q39753803 | ||
| Hepatocyte growth factor activator inhibitor type 1 regulates epithelial to mesenchymal transition through membrane-bound serine proteinases | Q39882808 | ||
| Expression of hepatocyte growth factor activator inhibitors (HAI-1 and HAI-2) in ovarian cancer. | Q39894457 | ||
| An epigenetic genome-wide screen identifies SPINT2 as a novel tumor suppressor gene in pediatric medulloblastoma | Q39910333 | ||
| Expression of hepatocyte growth factor activator inhibitor type 1 on the epithelial cell surface is regulated by hypoxic and oxidative stresses | Q39943520 | ||
| Activation of hepatocyte growth factor activator zymogen (pro-HGFA) by human kallikrein 1-related peptidases. | Q40020532 | ||
| Functional epigenomics approach to identify methylated candidate tumour suppressor genes in renal cell carcinoma | Q40025069 | ||
| Hepatocyte growth factor activation inhibitors (HAI-1 and HAI-2) regulate HGF-induced invasion of human breast cancer cells | Q40300349 | ||
| Structural and functional basis of the serine protease-like hepatocyte growth factor beta-chain in Met binding and signaling | Q40541604 | ||
| Expression of hepatocyte growth factor/scatter factor, its activator, inhibitors and the c-Met receptor in human cancer cells | Q40779798 | ||
| Hepatocyte growth factor activator inhibitor type 2 lacking the first Kunitz-type serine proteinase inhibitor domain is a predominant product in mouse but not in human | Q40970260 | ||
| Evaluation of hepatocyte growth factor activator inhibitor expression in normal and malignant colonic mucosa | Q41021185 | ||
| Activation of hepatocyte growth factor/scatter factor in colorectal carcinoma | Q42496244 | ||
| Concomitant expression of hepatocyte growth factor (HGF), HGF activator and c-met genes in human glioma cells in vitro | Q42803690 | ||
| Loss of the matriptase inhibitor HAI‐2 during prostate cancer progression | Q42945644 | ||
| The optimal activity of a pseudozymogen form of recombinant matriptase under the mildly acidic pH and low ionic strength conditions | Q43240327 | ||
| Reduced expression of hepatocyte growth factor activator inhibitor type-2/placental bikunin (HAI-2/PB) in human glioblastomas: implication for anti-invasive role of HAI-2/PB in glioblastoma cells | Q43658863 | ||
| Mouse hepatocyte growth factor (HGF) activator inhibitor type 2 lacking the first Kunitz domain potently inhibits the HGF activator | Q43858832 | ||
| Functional characterization of Kunitz domains in hepatocyte growth factor activator inhibitor type 1. | Q43862930 | ||
| Expression of the serine protease matriptase and its inhibitor HAI-1 in epithelial ovarian cancer: correlation with clinical outcome and tumor clinicopathological parameters | Q43955718 | ||
| Acid pH in tumors and its potential for therapeutic exploitation | Q44056533 | ||
| Tissue microarray analysis of hepatocyte growth factor/Met pathway components reveals a role for Met, matriptase, and hepatocyte growth factor activator inhibitor 1 in the progression of node-negative breast cancer | Q44342338 | ||
| Characterization of matriptase expression in normal human tissues | Q44519409 | ||
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 4 | |
| P304 | page(s) | 1890-1904 | |
| P577 | publication date | 2014-09-29 | |
| P1433 | published in | Cancers | Q27722963 |
| P1476 | title | Mechanisms of hepatocyte growth factor activation in cancer tissues | |
| P478 | volume | 6 |
| Q58108782 | 3-Cl-AHPC inhibits pro-HGF maturation by inducing matriptase/HAI-1 complex formation |
| Q55456643 | Aberrant methylation and silencing of the SPINT2 gene in high-grade gliomas. |
| Q47303095 | Activated HGF-c-Met Axis in Head and Neck Cancer |
| Q42058767 | CDKN3 expression is negatively associated with pathological tumor stage and CDKN3 inhibition promotes cell survival in hepatocellular carcinoma |
| Q37737964 | Carboxylate derivatives of tributyltin (IV) complexes as anticancer and antileishmanial agents. |
| Q38433828 | Design and Synthesis of Nonpeptide Inhibitors of Hepatocyte Growth Factor Activation |
| Q92855878 | Distinct Localization of Mature HGF from its Precursor Form in Developing and Repairing the Stomach |
| Q37650102 | Effects of HGF gene polymorphisms and protein expression on transhepatic arterial chemotherapeutic embolism efficacy and prognosis in patients with primary liver cancer |
| Q49545332 | Engineering a potent inhibitor of matriptase from the natural hepatocyte growth factor activator inhibitor type-1 (HAI-1) protein. |
| Q52726970 | Expression of serine peptidase inhibitor Kunitz type 1 in differentiated thyroid cancer. |
| Q57791826 | Extracellular Matrix Influencing HGF/c-MET Signaling Pathway: Impact on Cancer Progression |
| Q37544362 | Functional and therapeutic relevance of hepatocyte growth factor/c-MET signaling in synovial sarcoma |
| Q38490458 | Gene of the month: MET. |
| Q58555323 | Hepatocyte Growth Factor Activator: A Proteinase Linking Tissue Injury with Repair |
| Q38831784 | Hepatocyte Growth Factor, a Key Tumor-Promoting Factor in the Tumor Microenvironment |
| Q55343941 | Hepatocyte growth factor activator inhibitor type-2 (HAI-2)/SPINT2 contributes to invasive growth of oral squamous cell carcinoma cells. |
| Q37735624 | Hepatocyte growth factor/MET in cancer progression and biomarker discovery |
| Q98303275 | Inhibition of TMPRSS2 by HAI-2 reduces prostate cancer cell invasion and metastasis |
| Q42254033 | Inhibition of nuclear factor-κB signaling suppresses Spint1-deletion-induced tumor susceptibility in the ApcMin/+ model. |
| Q39816968 | Inhibition of pro-HGF activation by SRI31215, a novel approach to block oncogenic HGF/MET signaling |
| Q52318134 | Known and novel roles of the MET oncogene in cancer: a coherent approach to targeted therapy. |
| Q98568291 | Large-scale discovery of male reproductive tract-specific genes through analysis of RNA-seq datasets |
| Q60909538 | MET/HGF Co-Targeting in Pancreatic Cancer: A Tool to Provide Insight into the Tumor/Stroma Crosstalk |
| Q92126270 | Macrocyclic peptide-based inhibition and imaging of hepatocyte growth factor |
| Q50423780 | Molecular Regulation of Sprouting Angiogenesis |
| Q54254288 | Plasma macrophage-stimulating protein and hepatocyte growth factor levels are associated with prostate cancer progression. |
| Q92715008 | Potential role of HGF-PARP-1 signaling in invasion of ovarian cancer cells |
| Q41051656 | Probing conformational and functional states of human hepatocyte growth factor by a panel of monoclonal antibodies |
| Q47133508 | Prognostic significance of hepatocyte growth factor activator inhibitor type 1 (HAI-1) immunoreactivity in pancreatic ductal adenocarcinoma |
| Q39428273 | Role and Therapeutic Targeting of the HGF/MET Pathway in Glioblastoma |
| Q52675438 | Role of the Nervous System in Tumor Angiogenesis. |
| Q97074416 | Structural and Functional Insight Into the Glycosylation Impact Upon the HGF/c-Met Signaling Pathway |
| Q38297235 | Targeting the MET pathway for potential treatment of NSCLC. |
| Q41825773 | Targeting the tumor-promoting microenvironment in MET-amplified NSCLC cells with a novel inhibitor of pro-HGF activation. |
| Q42778244 | The type II transmembrane serine protease matriptase cleaves the amyloid precursor protein and reduces its processing to β amyloid |
| Q47676243 | Transcriptome-wide analysis suggests that temporal changes in the relative contributions of hyperplasia, hypertrophy and apoptosis underlie liver growth in pregnant mice |
| Q38790211 | Understanding STAT3 signaling in cardiac ischemia. |
| Q58760425 | Updates on the hepatocyte growth factor/c-Met axis in hepatocellular carcinoma and its therapeutic implications |
| Q38793227 | α-Ketobenzothiazole Serine Protease Inhibitors of Aberrant HGF/c-MET and MSP/RON Kinase Pathway Signaling in Cancer |
Search more.